Review: The problem of diabetic nephropathy and practical prevention of its progression

Abstract

In common with all countries in the developed world, the United Kingdom is experiencing a dramatic increase in the incidence of diabetes and chronic kidney disease. The most common cause of renal impairment is diabetes. The evolution of diabetic nephropathy is usually predictable with evidence-based interventions available at each stage. This review examines this evidence and gives practical advice on the management of patients with diabetic nephropathy. Br J Diabetes Vasc Dis, 2008; 8: 272—277

Keywords

cardiovascular morbidity and mortality diabetic nephropathy renin—angiotensin system

Get full access to this article

View all access options for this article.

References

Ritz E. , Rychlik I. , Locatelli F. , Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.

Adler AI , Stevens RJ , Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.

Allen KV , Walker JD Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care 2003;26:2389-91.

Gambaro G. , Kinalska I. , Oksa A. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615-25.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy ? Diabet Med 2008; 25(suppl 2):25-9.

National Institute for Health and Clinical Excellence. The management of type 2 diabetes. London: NICE, 2008.

Keller CK , Bergis KH , Fliser D. , Ritz E. Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 1996;7:2627-35.

10.

Ritz E. , Orth SR Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.

11.

Ruggenenti P. , Fassi A. , Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.

12.

Patel A. , MacMahon S. , Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.

13.

Huang XR , Chen WY , Truong LD , Lan HY Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47.

14.

Parving HH , Lehnert H. , Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

15.

Makino H. , Haneda M. , Babazono T. et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577-8.

16.

Mogensen CE , Neldam S. , Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-4.

17.

Parving HH , Persson F. , Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy . N Engl J Med 2008;358:2433-46.

18.

Barnett AH , Bain SC , Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.

19.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.

20.

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

21.

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

22.

Staessen JA , Wang JG , Ginocchio G. et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997;15:1579-92.

23.

Parving HH , de Zeeuw D. , Cooper ME et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008;19:771-9.

24.

Penno G. , Chaturvedi N. , Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998 ;47:1507-11.

25.

Fujisawa T. , Ikegami H. , Kawaguchi Y. et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998;41:47-53.

26.

Ritz E. , Ogata H. , Orth SR Smoking: a factor promoting onset and progression of diabetic nephropathy . Diabetes Metab 2000;26(suppl 4): 54-63.

27.

Wanner C. , Krane V. , Marz W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-48.

28.

Tonolo G. , Ciccarese M. , Brizzi P. et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-5.

29.

Pedrini MT , Levey AS , Lau J. et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996;124:627-32.

30.

Klahr S. , Levey AS , Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.